Highly effective treatment with tacrolimus ointment in an adolescent with oral graft-versus-host disease

Bauters, Tieneke; Bordon, Victoria; Velde, Veronique Van De; Lancker, Sophie Van; Robays, Hugo; Benoît, Yves; Laureys, Geneviève

doi:10.1007/s11096-010-9386-9

“…Normally, skin, liver and/or digestive tract are targets of aGVHD, however cGVHD is characterized by selective damage to the skin and mucosa, hair and/or nails, eyes, liver, lungs, gastrointestinal tract and muscle fasciae [7,8].…”

Section: Acute Gvhd (Agvhd)mentioning

confidence: 99%

“…The topical treatment might improve clinical response and prevents the patient from side effect of systemically used drugs [3,5,7,8,[14][15][16]. Solutions are used mainly when manifestation are generalized, whereas gels, creams and ointments are used for localized lesions, it is very easy to apply with finger or gauze, preferable gels due to their hydrofilic properties [5,15].…”

Section: Treatmentmentioning

confidence: 99%

“…Graft-versus-host disease (GVHD) is one of the principal complications of allo-HSCT and it is important cause of morbidity and mortality among patients undergoing HSCT, resulting a severe impairment of the quality of life among survivors, and it is likely to occur if the host receives a graft from an unrelated donor, or if the host or donor is older [3,7,8].…”

Section: Introductionmentioning

confidence: 99%

“…Traditionally, when it targets the immune system, by definition, if seen before Day +100 it is called as acute GVHD (aGVHD), but if it occurs after day 100 it is defined chronic GVHD, however, according to NIH Consensus criteria it is recommended to classify GVHD based on characteristic symptoms and signs rather than a rigid temporal definition [2,3,5,8,10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Oral chronic graft-versus-host disease: A short review

Hsieh¹,

Souza²,

Paula³

et al. 2016

Trends in Transplant

0

View full text Add to dashboard Cite

Allogeneic Hematopoietic Steam Cell Transplantation (allo-HSCT) treat a wide range of malignancies, including: neoplastic and non-neoplastic hematologic disease and immune deficiency states, and autoimmune disease. Chronic Graft-versus-host disease (cGVHD) is a major late complication of allo-HSCT, representing a clinical syndrome characterized by complex allogeneic and autoimmune dysregulation of the immune system, leading cause of non-relapse-related morbility and mortality among long-term transplant survivors. The oral cavity is frequently involved, as the second most common site involved after skin due to HSCT.The spectrum of clinical manifestation and histopathological characteristics of oral cGVHD are similar to several autoimmune conditions including Sjögren syndrome, oral lichen planus and scleroderma.Ancillary therapy is used for symptomatic oral mucosal or erythematous or ulcerative disease in GVHD treatment by using routine systemic drugs, several topical treatments as corticosteroids, non-corticosteroids, immunosuppressants, and phototherapy. For affected salivary glands, artificial saliva or saliva stimulators are commonly used to relief the xerostomia symptoms.

show abstract

“…Annually, it has increased steadily over the past three decades, worldwide 15.000 out of over 40.000 individuals are performed with cells an allogeneic donor by receiving HSCT [2,3,6]. Graft-versus-host disease (GVHD) is one of the principal complications of allo-HSCT and it is important cause of morbidity and mortality among patients undergoing HSCT, resulting a severe impairment of the quality of life among survivors, and it is likely to occur if the host receives a graft from an unrelated donor, or if the host or donor is older [3,7,8].…”

Section: Introductionmentioning

confidence: 99%

Oral chronic graft-versus-host disease: A short review

Hsieh¹,

Souza²,

Paula³

et al. 2016

Transplant Open

0

View full text Add to dashboard Cite

Allogeneic Hematopoietic Steam Cell Transplantation (allo-HSCT) treat a wide range of malignancies, including: neoplastic and non-neoplastic hematologic disease and immune deficiency states, and autoimmune disease. Chronic Graft-versus-host disease (cGVHD) is a major late complication of allo-HSCT, representing a clinical syndrome characterized by complex allogeneic and autoimmune dysregulation of the immune system, leading cause of non-relapse-related morbility and mortality among long-term transplant survivors. The oral cavity is frequently involved, as the second most common site involved after skin due to HSCT.The spectrum of clinical manifestation and histopathological characteristics of oral cGVHD are similar to several autoimmune conditions including Sjögren syndrome, oral lichen planus and scleroderma.Ancillary therapy is used for symptomatic oral mucosal or erythematous or ulcerative disease in GVHD treatment by using routine systemic drugs, several topical treatments as corticosteroids, non-corticosteroids, immunosuppressants, and phototherapy. For affected salivary glands, artificial saliva or saliva stimulators are commonly used to relief the xerostomia symptoms.

show abstract

Oral Squamous Cell Carcinomas in Patient with Graft Versus-Host Disease Following Allogenic Bone Marrow Transplantation: A Case Report during Mutant COVID-19 Pandemic

Salah¹,

Elturki²,

Swaisi³

et al. 2021

JDOA

0

View full text Add to dashboard Cite

Aplastic anaemia is a severe haematological disorder characterized by an inadequate number of hematopoietic stem cells, resulting in pancytopenia, formed by a hypocellular bone marrow. Disorders of this nature are widely treated with haematopoietic stem cell transplantation (HSCT). A potential chronic complication following (HSCT) is the growth of secondary malignancies. Notably, patients suffering from chronic graft versus host disease (cGvHD) secondary to HSCT have been shown to be more susceptible to oral squamous cell carcinoma (OSCC). Here, we present a rare case of a 30-year-old Libyan woman treated with HSCT for aplastic anaemia, with subsequent complications of cGvHD and OSCC after few months of HSCT. These carcinomatous lesions were detected in the buccal gingiva and retromolar pad area at the age of 31. The present case report emphasizes the connection between oral cGvHD and OSCC, and the potential appearance of OSCC after HSCT at any time of patient life. Thus, closer follow-up is mandatory for all patients treated with HSCT who developed cGvHD, and efficient cGvHD prevention and therapeutic approaches are needed.

show abstract

Highly effective treatment with tacrolimus ointment in an adolescent with oral graft-versus-host disease

Abstract: Although tacrolimus ointment is not licensed for the indication of oral GvHD, this case report provides preliminary evidence for a potential effectiveness of using tacrolimus in case of failure when GvHD is resistant.

Cited by 3 publications

References 7 publications

Oral chronic graft-versus-host disease: A short review

Oral chronic graft-versus-host disease: A short review

Oral chronic graft-versus-host disease: A short review

Oral Squamous Cell Carcinomas in Patient with Graft Versus-Host Disease Following Allogenic Bone Marrow Transplantation: A Case Report during Mutant COVID-19 Pandemic

Contact Info

Product

Resources

About